191 related articles for article (PubMed ID: 34584911)
1. Development of alternative gene transfer techniques for
Noda M; Tatsumi K; Matsui H; Matsunari Y; Sato T; Fukuoka Y; Hotta A; Okano T; Kichikawa K; Sugimoto M; Shima M; Nishio K
Regen Ther; 2021 Dec; 18():347-354. PubMed ID: 34584911
[TBL] [Abstract][Full Text] [Related]
2. Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response.
Ozelo MC; Vidal B; Brown C; Notley C; Hegadorn C; Webster S; Harpell L; Ahlin J; Winterborn A; Handforth J; Arruda VR; Hough C; Lillicrap D
Blood; 2014 Jun; 123(26):4045-53. PubMed ID: 24829206
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
[TBL] [Abstract][Full Text] [Related]
4. A novel cell-sheet technology that achieves durable factor VIII delivery in a mouse model of hemophilia A.
Tatsumi K; Sugimoto M; Lillicrap D; Shima M; Ohashi K; Okano T; Matsui H
PLoS One; 2013; 8(12):e83280. PubMed ID: 24358271
[TBL] [Abstract][Full Text] [Related]
5. Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device.
Olgasi C; Borsotti C; Merlin S; Bergmann T; Bittorf P; Adewoye AB; Wragg N; Patterson K; Calabria A; Benedicenti F; Cucci A; Borchiellini A; Pollio B; Montini E; Mazzuca DM; Zierau M; Stolzing A; Toleikis PM; Braspenning J; Follenzi A
Mol Ther Methods Clin Dev; 2021 Dec; 23():551-566. PubMed ID: 34853801
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for the hemophilias.
VandenDriessche T; Collen D; Chuah MK
J Thromb Haemost; 2003 Jul; 1(7):1550-8. PubMed ID: 12871290
[TBL] [Abstract][Full Text] [Related]
7. Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche T; Chuah MK
Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
[TBL] [Abstract][Full Text] [Related]
8. Storage and regulated secretion of factor VIII in blood outgrowth endothelial cells.
van den Biggelaar M; Bouwens EA; Kootstra NA; Hebbel RP; Voorberg J; Mertens K
Haematologica; 2009 May; 94(5):670-8. PubMed ID: 19336741
[TBL] [Abstract][Full Text] [Related]
9. Etranacogene dezaparvovec for hemophilia B gene therapy.
Thornburg CD
Ther Adv Rare Dis; 2021; 2():26330040211058896. PubMed ID: 37181105
[TBL] [Abstract][Full Text] [Related]
10. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
High KA
Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
[TBL] [Abstract][Full Text] [Related]
12. Ex Vivo Stromal Cell Electroporation of Factor IX cDNA for Treatment of Hemophilia B.
Keating A; Nolan E; Filshie R; Dev SB
Methods Mol Med; 2000; 37():359-68. PubMed ID: 21445754
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of canine hemophilia by continuous expression of canine FVIIa.
Margaritis P; Roy E; Aljamali MN; Downey HD; Giger U; Zhou S; Merricks E; Dillow A; Ezban M; Nichols TC; High KA
Blood; 2009 Apr; 113(16):3682-9. PubMed ID: 19109232
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for hemophilia.
Chuah MK; Collen D; VandenDriessche T
J Gene Med; 2001; 3(1):3-20. PubMed ID: 11269333
[TBL] [Abstract][Full Text] [Related]
15. Viral vector-mediated gene therapy for hemophilia.
VandenDriessche T; Collen D; Chuah MK
Curr Gene Ther; 2001 Sep; 1(3):301-15. PubMed ID: 12109144
[TBL] [Abstract][Full Text] [Related]
16. AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of life.
Doshi BS; Samelson-Jones BJ; Nichols TC; Merricks EP; Siner JL; French RA; Lee BJ; Arruda VR; Callan MB
Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101205. PubMed ID: 38374963
[TBL] [Abstract][Full Text] [Related]
17. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy.
Xu L; Nichols TC; Sarkar R; McCorquodale S; Bellinger DA; Ponder KP
Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6080-5. PubMed ID: 15837921
[TBL] [Abstract][Full Text] [Related]
18. Clinical gene transfer studies for hemophilia A.
Chuah MK; Collen D; VandenDriessche T
Semin Thromb Hemost; 2004 Apr; 30(2):249-56. PubMed ID: 15118936
[TBL] [Abstract][Full Text] [Related]
19. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.
Jiang H; Lillicrap D; Patarroyo-White S; Liu T; Qian X; Scallan CD; Powell S; Keller T; McMurray M; Labelle A; Nagy D; Vargas JA; Zhou S; Couto LB; Pierce GF
Blood; 2006 Jul; 108(1):107-15. PubMed ID: 16522813
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy for hemophilia.
Lynch CM
Curr Opin Mol Ther; 1999 Aug; 1(4):493-9. PubMed ID: 11713765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
